Ignite
Leading the future of science with precision testing, innovative research, and expert consultation
Ignite
Driving Change In Precision Medicine
Creating Tomorrow's Solutions Today.
Crohn's Disease
Rheumatoid Arthritis
Inflammatory Bowel Disease
Psoriatic Arthritis
Leaders of precision testing solutions for optimal performance and quality assurance
Our mission
Advancing scientific discovery through precise testing and innovative research for global impact and excellence.
98%
Accuracy
Determined to prevent current industry inefficiencies
Company Timeline
2022
Ignite Biomedical established with the primary goal of eliminating inefficient healthcare spending related to medication use. Our goal is to ensure the right patient receives the right medication at the right time, while reducing waste and optimizing clinical outcomes.
2023
• Pre-seed funding round closed, raising $1.5 million to use for discovery and development.
• Established a partnership with Liquid Biosciences to discover novel biomarkers for autoimmune diseases.
These diseases include:
• Inflammatory Bowel Disease
• Rheumatoid Arthritis
• Crohn's Disease
• Psoriatic Arthritis
• Plaque Psoriasis
• Initiate partnership with SmartHealth Diagnostics for expertise and access to key laboratory services that dramatically speed up develop time and begin assay and test discovery and development.
• Established a partnership with Liquid Biosciences to discover novel biomarkers for autoimmune diseases.
These diseases include:
• Inflammatory Bowel Disease
• Rheumatoid Arthritis
• Crohn's Disease
• Psoriatic Arthritis
• Plaque Psoriasis
• Initiate partnership with SmartHealth Diagnostics for expertise and access to key laboratory services that dramatically speed up develop time and begin assay and test discovery and development.
2024
• Successfully completed the analytical validation of its Tumor Necrosis Factor-alpha Inhibitor (TNFi) Treatment Response Predictor (TRP). This milestone demonstrates the test's exceptional performance across critical parameters, including precision, repeatability, linearity, sensitivity, stability, and robustness.
• With a new company valuation, we began our second funding round for Clinical Validation and further developments.
“What an incredible milestone we have achieved! The successful analytical validation of our TNF-alpha Inhibitor Treatment Response Predictor not only confirms the accuracy of our test but also underscores its potential impact on patient care. We are thrilled to advance towards clinical validation, as this step will bring us closer to transforming treatment outcomes for patients with inflammatory bowel disease and beyond.”
Claudio Faria,
Co-founder and CEO of Ignite Biomedical
2025-2026
Pipeline
Pipeline
Begin Clinical Validity phase:
• 19-12 month period
• 900 patients with inflammatory disease
• Partnership with SmartHealth Diagnostics and a large clinical research organization (CRO)
• Aim to obtain Clinical Laboratory Improvement Amendment (CLIA) certification
Pre-Launch Activities
• Conduct clinical utility study
• Test portfolio with Palmetto MolDX program
• Negotiate pricing with Centers for Medicare & Medicaid Services (CMS)
•Meet with managed care and health system executives
• Commence general marketing and sales (primarily to Medicare patients)
Projects Overview:
• IGNB-001A IBD TNFI Precision Blood Test
(Analytically Validated)
• IGNB-001B RA TNFI Precision Blood Test
(In Discovery)
• IGNB-001C PSA/PSO TNFI Precision Blood Test
(In Discovery)
• IGNB-002 IBD Diagnostic and Prognostic Blood Test
(Discovery Complete)
• IGNB-003 IBD Next-Gen a4B7 Precision Blood Test
(Discovery Complete)
• IGNB-101 Substance Use Disorder Diagnostic (Discovery Complete)
• 19-12 month period
• 900 patients with inflammatory disease
• Partnership with SmartHealth Diagnostics and a large clinical research organization (CRO)
• Aim to obtain Clinical Laboratory Improvement Amendment (CLIA) certification
Pre-Launch Activities
• Conduct clinical utility study
• Test portfolio with Palmetto MolDX program
• Negotiate pricing with Centers for Medicare & Medicaid Services (CMS)
•Meet with managed care and health system executives
• Commence general marketing and sales (primarily to Medicare patients)
Projects Overview:
• IGNB-001A IBD TNFI Precision Blood Test
(Analytically Validated)
• IGNB-001B RA TNFI Precision Blood Test
(In Discovery)
• IGNB-001C PSA/PSO TNFI Precision Blood Test
(In Discovery)
• IGNB-002 IBD Diagnostic and Prognostic Blood Test
(Discovery Complete)
• IGNB-003 IBD Next-Gen a4B7 Precision Blood Test
(Discovery Complete)
• IGNB-101 Substance Use Disorder Diagnostic (Discovery Complete)
Our Leaders
A place for
Great innovation
discovery
.png)